Micronutrient-deficiency control programs have been greatly extended at the national level in the last 10 to 15 years. However, rigorous evaluations of these are scarce, so that conclusions on impact are tentative and based mainly on indirect evidence. The coverage of vitamin A capsule distribution programs has exceeded 70% in most study countries. In countries implementing national iodized salt programs, the coverage reaches 60% to 90% of households with adequately iodized salt. Of the three micronutrients, coverage of iron tablet supplementation is the least well documented due to inadequate program monitoring systems and population survey data. Supplementation of preschool children 6 to 59 months of age with vitamin A capsules has plausibly contributed to the reduction in clinical vitamin A deficiency and its near-elimination in many countries. The impact of vitamin A capsule supplementation on children's biochemical vitamin A status (serum retinol) in national programs may be less. National data on salt iodization show a consistent relation to reduced prevalence of iodine-deficiency disorder symptoms (goiter); the rates of cretinism and other results of iodine deficiency are almost certainly falling too. The evaluation of the impact of salt iodization programs on biochemical iodine status is limited by a lack of data. Although trials have demonstrated the efficacy of iron supplementation in reducing the prevalence of anemia, the interpretation of national-level data is not so clear. Given the substantial financial and technical commitment required to implement national micronutrient-deficiency control programs, it is vital that investment enable the evaluation of the impact of these programs. It is becoming increasingly important to collect data on subclinical deficiency (e.g., biochemical data) to assess program impact.
Introduction
This paper, the third in the series entitled "Lessons from Successful Micronutrient Programs," takes up the question of the evidence for the impact of micronutrientdeficiency control interventions, examining how far it is known whether national programs are associated with improvement in indicators of nutritional status, and by how much. This is based on a project involving 12 countries, all but one in Asia: Bangladesh, Cambodia, China, India, Indonesia, Laos, Myanmar, Philippines, South Africa, Sri Lanka, Thailand, and Vietnam.
Numerous efficacy trials starting decades ago have been conducted to assess the effects expected from large-scale micronutrient-deficiency control programs. Iodine provides a good model of systematic development of intervention. Thus, the importance of iodine along with the efficacy of supplementation was shown in the 1960s to the 1980s [1] , leading to some well-documented national programs that greatly reduced iodine-deficiency disorders, notably in Latin America [2] . Understanding vitamin A interventions has been more complicated, with the focus shifting from preventing eye damage to reducing mortality and more limited testing of the efficacy of different approaches; this is discussed in the next section in some detail. Iron deficiency and anemia have been concerns for many years, but here there is a crucial gap between the efficacy of approaches at the pilot level (such as ferrous sulfate supplementation) and the limited known success (lack of data is a major problem) of these approaches in routine programs.
The research needed to move from efficacy at the pilot level to broad effectiveness has been limited. Hence the size and rate of reduction of deficiency to be expected from large-scale programs are not always clear. With most developing countries now implementing at least one (and in many cases three) nationwide micronutrient-deficiency control program or programs, it has become increasingly important to estimate the actual effects of these interventions on large populations in order to fine-tune their utility and support their continuation. This requires specific and carefully designed evaluations. However, these are very scarce for national (or large-scale) programs.
The extent of the impact of micronutrient-deficiency control programs in Asia can nonetheless be assessed to some degree. Most countries providing case studies have some outcome data on micronutrient status and on program implementation. However, almost all available outcome data are for clinical measures of micronutrient deficiencies. For vitamin A, the clinical prevalences are so low that this measure is not very suitable for evaluation, requiring huge samples to estimate effects. On the other hand, few survey results are available on subclinical measurements among less severely affected populations, even though subclinical prevalences are higher and thus potentially more suitable for evaluation. Although some project countries have multiple rounds of data on clinical indicators of vitamin A deficiency, only the Philippines has two rounds of national data on serum retinol. (China, Indonesia, South Africa, and Vietnam also have multiple rounds of serum retinol data available, but the survey coverage in all cases is subnational, and for many of these countries, information on the comparability of the serum retinol surveys was not available.) Likewise, almost all countries have at least two rounds of goiter data; however, only three countries reported multiple rounds of national data on urinary iodine excretion (China also has multiple rounds of urinary iodine excretion data available; however, only data on median urinary iodine values could be obtained.) At the same time, process data on implementation may be available, but these data are not often linked (except perhaps at the provincial levels) to the outcome, thus precluding much useful evaluation. The prevalence of anemia among pregnant women is assessed, but program coverage data are scarce for iron too. Few of the anemia prevalence data can therefore be linked to iron-supplementation programs.
The results on the prevalence of deficiencies from project countries have been compiled here to assess their trends and to shed some light on program impact achieved to date, as best as possible from the available data. The trends for clinical vitamin A deficiency are reasonably clear both for individual project countries and across countries in Asia. Most countries have considerable coverage data on vitamin A programs, so that some linkage can be attempted. The prevalence trends assessed by biochemical data on vitamin A deficiency are not as clear. For iodine deficiency, most country data indicate a decrease in prevalence with implementation of the national iodized salt program. This trend is observed for both clinical (goiter detected by palpation) and biochemical (urinary iodine excretion) indicators. In the case of iron-deficiency anemia, not as many conclusions can be drawn. Few countries have anemia data that can be linked to programs; only Thailand and Vietnam have prevalence and coverage data that allow for some crude assessment of program effectiveness.
For all three deficiencies, as a first step we have reviewed what results might be expected from effective implementation-mainly based on efficacy trials-as guidance to what to look for. The observed results are then related to the expected results, with focus on the situations with the most promising data.
Vitamin A What is known from efficacy trials
A literature search was done to explore the extent of the effect to be expected by supplementation of children with massive doses (200,000 IU) of vitamin A. A number of both controlled efficacy trials and uncontrolled community trials of periodic dosing were identified. Most efficacy trials observing the effects of supplementation used data on clinical signs of vitamin A deficiency that had been obtained prior to the wide-scale adoption of vitamin A-supplementation programs. Although much less in number, some trials to date have observed the effects of supplementation on biochemical indicators of vitamin A deficiency, such as low serum retinol; these trials are discussed later.
Range of efficacy demonstrated by clinical data on vitamin A deficiency
Most efficacy trials used high-dose (200,000 IU) vitamin A capsules at approximately six-month intervals. The results of 25 trials of vitamin A capsules (19 in Asia; 20 measuring clinical vitamin A deficiency) analyzed in a previous review [3] were largely consistent in showing a significant impact on clinical indicators of vitamin A deficiency, often bringing the prevalence to nearly zero. Examples are studies conducted in India [4, 5] ,* Indonesia [6] [7] [8] [9] , and the Philippines [10] .
The size of the impact varied considerably. For Bitot's * Gujral, Gopaldas T. USAID assisted ICDS impact evaluation project in Panchmahals (Gujarat) and Chandrapur (Maharasthra), 1984-1990, 1991. spots (X1B), the decrease in prevalence at 12-month follow-up ranged from 4.4 to 1.1 percentage points (4.7% to 0.3% in the study of Tarwotjo and co-workers [7] ; 1.1% to 0.1% in other Indonesian studies [8] [9] [10] [11] ). Keratomalacia was observed as an outcome measure in one study; the results showed an odds ratio of 12.5 for keratomalacia and receipt of dose [4] . The effect of supplementation on active xerophthalmia ranged from 4.7 to 1.6 percentage points of decrease in prevalence (from 6% to 1.3% in Vijayaraghavan and colleagues [5] , and from 1.9% to 0.3% in Sommer and co-authors [6] ).
Longer follow-up periods demonstrated sustained effects on clinical signs. In Vietnam, a two-year trial was conducted in which a vitamin A dose (200,000 IU) was provided twice yearly. The results of the trial indicated no cases of xerophthalmia among the experimental group at the end of the follow-up period [12] . In the Philippines, 200,000 IU vitamin A capsule supplementation was provided to children with xerophthalmia. The results showed a 2.7 percentage points decrease in xerophthalmia at 24 months of follow-up.* A study in India with a six-year follow-up also showed a beneficial impact of vitamin A supplementation: among those groups receiving twice-yearly vitamin A doses, the prevalence of active xerophthalmia decreased from 4% to 1% in one intervention area and from 12% to 1% in the second intervention area studied.** A few other trials have shown a lesser impact of vitamin A supplementation on clinical signs of deficiency. A trial in Sudan [13] showed little difference in the number of new cases of xerophthalmia after three doses of vitamin A were administered at sixmonth intervals. The prevalence of xerophthalmia was reported as 2.9% at baseline; after 18 months, it was 0.013% in the treated group and 0.015% in the control group, results that are hard to interpret. In the Philippines, no substantial difference in the frequency of xerophthalmia cases was found with the provision of vitamin A supplement (200,000 IU) to malnourished children (second and third degree underweight) every six months [14] . These results may indicate that under some conditions-possibly with other forms of malnutrition or underlying changes-the impact is reduced.
Some guidance as to the expected impact on clinical vitamin A deficiency from supplementation can be taken from these intervention trials. Overall, the results may be interpreted as showing that, whatever the starting prevalence, administration of vitamin A capsules in high doses every four to six months largely prevents new cases of eye signs and brings their prevalences down to nearly zero. Cautions in the interpretation of these results may be that existing Bitot's spots may persist and that the effect of vitamin A supplementation may be curtailed with concurrent protein-energy malnutrition. At the same time, since the starting prevalences of clinical vitamin A deficiency are very low (almost always less than 5%, and often only 1%), this indicator is not ideal for detecting change.
Range of efficacy demonstrated by biochemical data on vitamin A deficiency
Much less is known about the effect to be expected on serum retinol from supplementation. This is important, since subclinical vitamin A deficiency is far more prevalent and, moreover, it is thought that the mortalityreducing effects of vitamin A interventions are gained by reducing subclinical deficiency [15] . A number of studies on the effect of supplementation (to children) on serum retinol were extracted from the literature; the results are summarized in table 1, as no such compilation was identified. The time over which the effect of supplementation persisted became of concern with results from the Philippines presented in this project. Therefore the efficacy trials were reexamined to look into this aspect. The serum retinol studies available are relatively few in number, and the findings across these studies are not always consistent. The extent of impact ranged from a 12 percentage points decrease in vitamin A deficiency as indicated by low serum retinol (< 20 µg/dl) [16] to no biochemical improvement indicated among a group supplemented with vitamin A capsules [10] .
The largest decrease in the prevalence of subclinical vitamin A deficiency was demonstrated in a trial conducted in Brazil by Araujo and co-workers [16] , where the prevalence of serum retinol levels < 20 µg/dl dropped from 16.3% to 4.3% among preschool children after supplementation with vitamin A. However, because the study did not include a control group, the extent of the decrease in prevalence cannot be distinguished from the underlying trend in vitamin A deficiency. Ramakrishnan showed an effect of vitamin A capsules on Bitot's spots, but a much weaker impact on serum retinol. Likewise, although Solon and co-authors [10] documented an effect on clinical signs of vitamin A deficiency (the prevalence of xerophthalmia dropped from 3.1% to 0.6% among the group supplemented with vitamin A), the study showed no biochemical improvement from capsule supplementation alone; only the intervention group provided with a weekly supply (two packets per family per day) of monosodium glutamate (MSG) fortified with vitamin A showed an increase in serum retinol (from 21.0 to 28.5 µg/100 ml). Few biochemical data exist to assess the potential protective period of the recommended dose of vitamin A supplementation. Only two such efficacy studies could be identified. One of these trials [21] showed that children supplemented with 200,000 IU retained significantly higher serum retinol values three and six months following supplementation than did children supplemented with 100,000 IU (the serum retinol values at baseline, three months, and sixth months for the 100,000 IU vs. the 200,000 IU group were 0.55 vs. 0.54, 0.53 vs. 0.63, and 0.81 vs. 0.89 µmol/L, respectively). A second study, conducted by Perlas et al. [22] in the Philippines, showed an effect of vitamin A supplementation on serum retinol, with a protective effect of the capsules that seemed to last up to about four months. The results of the Perlas study are described in more detail below, under General Evaluation Findings.
In addition to the above trials, some studies have explored the effect of supplementation on serum retinol among women postpartum. Studies by Roy et al. [23] , Stoltzfus et al. [24] , Rice et al. [25] , and Tanumihardjo et al. [26] have shown that, in general, vitamin A supplementation to women postpartum is an efficacious strategy for controlling vitamin A deficiency among lactating women. This was indicated in the study of Rice et al. [25] by differences in mean milk vitamin A concentration among mothers and by differences in serum retinol and modified retinol dose response (MRDR) values among infants in different intervention groups; as in the study of Roy et al. [23] , among women less effect was observed on serum retinol than among infants. In fact, in the study of Rice et al., a significant difference in serum retinol values was not demonstrated between any of the three groups of lactating women at any time during data collection.
In a controlled trial by Stoltzfus et al. [24] , lactating women were supplemented with vitamin A (300,000 IU) or placebo shortly after delivery. The results showed that the mean serum retinol concentration for the intervention group was higher than that for the placebo group, and this finding was observed at both three and six months postpartum. The extent of the impact demonstrated, however, was relatively small: a difference of 0.15 µmol/L between the inter-vention and control groups (1.39 vs. 1.24 µmol/L) at three months. The same range of effect (0.15 µmol/L difference) was observed between the intervention and control groups (1.23 vs.1.08 µmol/L) at six months of follow-up. The findings suggest that the extent of the effect to be expected by vitamin A supplementation on serum retinol among lactating women should be considered. If consistent across studies, the observed results could have wider implications for indicators to include in future evaluations of postpartum vitamin Asupplementation programs.
Changes in serum retinol after administration of vitamin A capsules appear to be more dependent on the length of time after the dose than are changes in clinical signs. In more than half the trials assessed (table 1), the serum retinol levels had returned to predose values by six months after the dose, and probably earlier. Thus, the efficacy data suggest that vitamin A capsule supplementation may not have a persistent effect on the subclinical deficiency, as measured by serum retinol. Therefore we are unsure about what to expect when serum retinol is used to evaluate large-scale programs involving administration of vitamin A capsules.
Methods applied to country-level prevalence data
Evaluation of programs by clinical data on vitamin A deficiency is possible, although using biochemical data in addition would be valuable because the prevalences of clinical signs are so low. In the case of most project countries, the prevalence of night-blindness is low enough that the number of people actually affected by night-blindness is very small. This makes it somewhat difficult to use clinical indicators of vitamin A deficiency to relate data to population estimates. Still, clinical data are what most countries have available, and therefore they remain the most available means of assessing program effectiveness in these countries.
Baseline and follow-up data as reported are listed in table 2. The calculation of the rate of change in prevalence in percentage points for a 10-year period (percentage points/10 years) for clinical vitamin A deficiency was as follows:
follow up prevalence -baseline prevalence × 10 years follow up year -baseline year Caution must guide the interpretation of the results both within and across countries. Very few countries (if any) have yet conducted rigorous evaluations of their national vitamin A-supplementation programs, with valid comparisons over time and with and without the program. Furthermore, in some cases different age groups have been used for surveys in different years. In others, baseline data (i.e., obtained prior to program implementation) could not be found for a country program. For these countries, the earliest known prevalence data were used. Coverage data on the percentage of members of the age group reported to receive vitamin A capsules for the (normally twice yearly) distribution are shown in figure 1 . Coverage data were used for the closest year possible to that of the follow-up prevalence data point, normally for the most recent year available. As discussed later, reported coverage based on administrative records from the vitamin A capsule distributions-usually the number of capsules compared with local data on population in the target age group-was generally higher than estimates derived (when available) from sample surveys of households; however, there was no way of correcting this, so the data in figure 1 should be viewed as probably a high estimate of the actual coverage.
Evaluation findings

Impact of programs on clinical indicators of vitamin A deficiency
The characteristics and clinical outcomes of the largescale programs reviewed here are compiled in table 2, drawing on the country studies [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] .* Comparing the results of repeated national surveys shows the prevalence of clinical vitamin A deficiency to be decreasing (column H). Across project countries in Asia, the rates of change in the clinical prevalence of vitamin A deficiency (night-blindness or Bitot's spots) nationally range from -0.15 to -0. 43 The decrease observed in clinical eye signs of vitamin A deficiency is, across project countries, in line with the trend demonstrated by a global assessment of trends in vitamin A deficiency (the prevalence of xerophthalmia, calculated by the sum of night-blindness and Bitot's spots, was the indicator used for assessing trends in vitamin A deficiency [38] ), which compared the results of repeated national surveys available from 8 countries with a total of 35 data points across time (13 national surveys and 22 subnational surveys, irrespective of intervention programs). The trend was estimated as -0.84 percentage point/10 years for South Asia and -0.18 percentage point/10 years for East Asia and the Pacific region; the global average was -0.43 percentage point/10 years [38, table 6 ]. The results available here from the country reports are thus generally in the same range as the previous estimates.
Although the trend of observed improvement in clinical vitamin A deficiency is anticipated, the rate of change shown by project countries might be smaller than expected from the range of effect typically demonstrated by efficacy trials. A 1.6 to 4.7 percentage point decrease in the prevalence of xerophthalmia was demonstrated across efficacy studies at one year of follow-up. For night-blindness, the trials in Indonesia [8] [9] [10] [11] showed a decrease of 0.87 percentage points over one year in the prevalence of night-blindness among the group supplemented with vitamin A, as compared with a decrease in the prevalence of nightblindness ranging from 0.17 to 1.76 percentage points per 10 years for national vitamin A supplementation programs implemented. (The rate of change indicated by Cambodia is not included in the range stated here, as the values shown are extreme outliers and represent subnational estimates.)
Of the project countries having outcome data, Bangladesh shows a particularly strong decrease in the prevalence of vitamin A deficiency across time. The vitamin A-supplementation program appears likely to have contributed to this, with very high reported coverage. Vitamin A supplementation to children in Bangladesh began in 1973, but coverage at this time was not reported. The earliest data point that could be identified for the prevalence of night-blindness was 1982. At that time, 3.6% of children 6 to 59 months of age were reported to have clinical signs of nightblindness. A second data point for night-blindness was collected in 1999 and showed a prevalence of 0.6% for children 12 to 59 months of age. The rate of change is calculated as a decrease of 1.76 percentage points in prevalence per 10 years.
Bangladesh has achieved coverage of greater than 80% since the integration of supplementation with national immunization days. For the most recent year for which prevalence data are available (1999), coverage of 99% was reported. However, the full extent of the decrease in deficiency is probably related not solely to supplementation, but also to the underlying decreasing trend in prevalence seen in other countries without programs (or with lower coverage).
In Cambodia, small-scale implementation of vitamin A supplementation began in 1993. In 1995, distribution of capsules through national immunization days was pilot tested in eight communes, and by 1996, capsule distribution was fully integrated with national immunization days. During years in which the vitamin A supplementation was integrated with national immunization days, high coverage rates were achieved. From 1995 to 1998, more than 95% of the target coverage was reached for every year, with the exception of the year 1997, for which coverage rates reaching 90% of the target were reported. The high prevalence reported at baseline, together with the high rate of coverage obtained by the program twice yearly, supports the reported dramatic improvement in prevalence of vitamin A deficiency (table 2) .
More common across project countries is a decrease in prevalence of around 0.5 percentage points per 10 years. Countries such as Indonesia and Vietnam (for 1988-1994) show rates of decrease of about this order. Although each of these countries has a fairly high program coverage, these are not as high as those achieved in Cambodia and Bangladesh. Indonesia, for example, reported coverage for the supplementation program as 66%. In 2000, Vietnam reported a coverage of 77% for the vitamin A program. Nonparticipants are likely to be the most remote and vulnerable.
India and Myanmar also show rates of decrease in clinical signs of vitamin A deficiency similar to those achieved in Indonesia and Vietnam, although in both of these countries, Bitot's spots is the indicator reported. Although Myanmar has reported especially high rates of program coverage (> 90% prior to integration with national immunization days and 99% in January 2000, when supplement distribution was integrated with national immunization days), the supplementation program in India has not achieved coverage rates of this magnitude. Although national program coverage data are not available for India, it appears, for example, that there was no state in which more than 40% of children received one dose of vitamin A in 1997. Given the marked difference in coverage between these programs, it is therefore interesting that a similar rate of decrease in Bitot's spots is indicated for the two countries. The similarity in the decrease in prevalence, despite the differences in program coverage, may again suggest that not all of the decrease in prevalence is attributable to program impact, but that an underlying improving trend is also present.
An interpretation of the efficacy data could be that when vitamin A capsules are provided under supervision, clinical vitamin A deficiency essentially disappears, and thus the rate of improvement is less important than the final prevalence. It is hard to judge with such low prevalences, but it seems plausible that clinical vitamin A deficiency was at significant levels in the baseline measurements (table 2, column E) and had reached lower levels, approaching zero, postintervention. What is less clear is how much of this was due to the underlying trend and how much to intervention. But given the combination of the high coverage data ( fig. 1 ) and the known efficacy, at least in terms of clinical vitamin A deficiency, it seems plausible that, at a minimum, the vitamin A capsule programs hastened the improvement in clinical vitamin A status.
Impact of programs on biochemical indicators of vitamin A deficiency
The Philippines is the only project country for which the effectiveness of the national vitamin A-supplementation program can be assessed from biochemical data. In other countries for which two rounds of serum retinol data are available (China, Indonesia, South Africa, and Vietnam), the data are for subnational areas and, although useful for assessing program impact for those areas, do not provide a complete picture of the effectiveness of the national program. The national vitamin A-supplementation program consists of twice-yearly distribution to children one to five years of age. The program began in 1993 and was reported to reach high coverage (> 80%) by 1995 (when it was known as ASAP [Arawa ng Sangkap Pinoy, or national micronutrient day in Tagalog]). For children one to five years of age, the 1993 and 1998 data both showed a shift upwards in the distribution of serum retinol levels, when data from the no-dose group were compared with the pooled data from children one to six months after dosing. Thus, some program impact was apparent [32] . On the other hand, the estimated national prevalence of low serum retinol actually increased slightly, from 35% to 38%, over the period [41] . This presented a dilemma that required more complex analysis to unravel.
The data available come from the Food and Nutrition Research Institute, which implemented National Nutrition Surveys in 1993 and 1998, collecting serum retinol data [41] . Additional variables included the age and sex of the child, participation in the national supplementation program, the month when the vitamin A dose (200,000 IU) was received, the month of data collection, and child anthropometric measurements, as well as information on other health-related variables. Although the data were not originally intended for program evaluation, their availability provided an unusual opportunity to investigate the effectiveness of the vitamin A-supplementation program for children both marginally and severely affected by vitamin A deficiency. The results drawn on here include those presented at the International Union of Nutritional Sciences in 2001 [32] and the results of further analyses presented at the International Vitamin A Consultative Group in 2003.* Some key results are shown in figure 2. Improvement in the prevalence of low (< 20 µg/dl) serum retinol levels was evident for the first two months after dosing, as compared with those in the survey who (for whatever reason) did not get a vitamin A capsule dose, shown by the top two lines in figure 2. The data also showed an increase in the mean serum retinol level from 22 to 25 µg/dl one month after dosing (3 µg/dl, a 14% increase); this was the only significant difference. The improvements in the prevalence of low serum retinol were comparable to the results seen in efficacy trials at two months (lower line in fig. 2 , from Perlas et al. [22] ). However, from about two months after dosing, the prevalence levels nearly returned to either the predose or the nondosed levels. The effects of supplementation on increasing serum retinol appeared more transient in the national results than in the efficacy trial. One possible explanation is the difference in the prevalence of deficiency prior to supplementation. Seasonality effects were also evident.
The national Food and Nutrition Research Institute data thus suggest a smaller effect of supplementation on serum retinol levels than that expected from the efficacy trial [22] . The protective period following dosage appears to be shorter-lived, with most of the effect disappearing one to three months after supplementation. Additionally, analysis according to age group showed that children under one year of age had the highest prevalence of deficient serum retinol and the lowest mean value of serum retinol. This difference was greater in 1998 than in 1993. This suggests that the increasing numbers of babies with serum retinol deficiency meant that the supplementation program for children one to five years old had a rising tide to stem.
Overall, the vitamin A capsule program in the Philippines may be effective in preventing a recurrence of clinical vitamin A deficiency, which is said to have virtually disappeared; but it is not apparently affecting the overall prevalence of subclinical vitamin A deficiency measured by serum retinol. These results are uncommon, since very few surveys of serum retinol have been repeated. The one other case identified in Asia, from Orissa and Andrha Pradesh in India [42] , showed similar transient effects of vitamin A capsules on serum retinol: in Orissa a similar temporary fall in prevalence was observed one month after dosing, and in Andrha Pradesh there was no reduction.
Conclusions
The only data presented that allowed any comparison between groups receiving and not receiving vitamin A capsules were those from the Philippines on subclinical vitamin A deficiency. The clinical data from all other countries were obtained before and during supplementation, with no comparison group, so evaluation conclusions are tentative.
The clinical data showed that, in the most recent measurements, eye signs of vitamin A deficiency (night-blindness and Bitot's spots) were reaching very low prevalences of 0.1% to 0.7% (average, 0.6%), as compared with 0.4% to 5.6% (average, 1.8%) presupplementation (table 3, columns E and F). We do know that there is an underlying trend toward a decrease in clinical vitamin A deficiency, which has been observed both prior to and during the supplementation programs in other studies [3, 23] . The question is: What values would the clinical vitamin A deficiency prevalences have reached without supplementation?
Since coverage of vitamin A capsules was consistently reported as above at least 60%, it is clear that supplementation was successfully launched and sustained, even if some vulnerable groups remained to be reached. The efficacy data show that when vitamin A capsules are provided, usually twice yearly (under some supervision in trials), clinical vitamin A deficiency is almost abolished. Therefore it is reasonable on this basis to ascribe the very low levels of clinical vitamin A deficiency now observed in these countries at least in part to the vitamin A capsule programs. On balance, vitamin A capsule supplementation can plausibly be credited with helping in the near-elimination of clinical vitamin A deficiency in these countries; but no doubt pockets of clinical deficiency persist.
The efficacy of vitamin A capsule distribution in raising serum retinol levels appears more variable (table 1). In the one case in which effectiveness could be studied in large-scale programs, in the Philippines, the effect of six-monthly doses of 200,000 IU of vitamin A to children one to five years of age at one to two months after the dose was modest, amounting to an increase in serum retinol of about 3 µg/dl (about 15%) and a reduction of 5 to 10 percentage points in the prevalence of serum retinol values below 20 µg/dl, from a prevalence of around 40% (fig. 2) . The effect persisted for around one to three months, after which the serum retinol returned to predose levels. This means that over several rounds of repeated six-monthly doses, no established downward trend is to be expected, but rather fluctuations returning to predose levels each time. This is in line with the findings of an actual small increase in the prevalence over the period of program implementation [41] .
It is uncertain whether the reduction of clinical and subclinical vitamin A deficiency resulting from the use of vitamin A capsules will be paralleled by a reduction in mortality, although the prevention of subclinical deficiency has been invoked as a mechanism for reducing mortality [15] . These results raise a question as to whether more frequent dosing (with other adaptations, such as targeting) would be advisable to ensure the intended impact on mortality (which has not been monitored). Modifications that could be considered include: » Giving top priority to supplementation to the mother shortly after delivery, and promoting breastfeeding; » Providing the supplement every three or four months to children one to five years of age; » Reexamining whether children 6 to 12 months of age can be supplemented, directly or through blended food or sprinkles; » Timing the mass supplementation program carefully in the light of seasonal effects; » Providing other supplements.
Iodine
What is known from efficacy trials
The efficacy of iodine interventions (by lipiodol injection, oral supplement, or iodized salt) for the prevention of deficiency is well established by the results of numerous controlled trials [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] . In these, iodine has been shown to prevent the various health consequences of iodine deficiency by a reduction in the frequency of irreversible outcomes and/or by an improvement among those populations having reversible consequences. The range of impact observed varies, in part, with the severity of deficiency among the population. In those areas with endemic and more severe levels of iodine deficiency, provision of iodine would be expected to have a greater benefit in both efficacy trials and large-scale programs. In most cases, goiter prevalence has been a key indicator, and there is no doubt that iodine is efficacious in reducing the goiter prevalence in iodine-deficient populations.
However, the rate at which goiter-as the usual measure of iodine-deficiency disorders-is expected to decline with an effective salt iodization program is less well known. The World Health Organization (WHO) has established criteria for assessing the severity of the problem of iodine-deficiency disorders and monitoring progress [55] . A goiter prevalence of less than 5% would be regarded as indicating the absence of an iodine-deficiency disorder problem, and clearly this is the eventual goal. What is unsure is the rate at which this can be expected to be achieved by universal salt iodization.
Methods applied to country-level evaluation data
Clinical and biochemical data on iodine deficiency, along with data on program coverage, have been compiled for the 12 project countries (tables 3 and 4). As for vitamin A, iodine-deficiency data were selected to measure baseline and during-intervention prevalence, as best as possible. For these purposes, the year of adoption of iodized salt legislation was selected to mark the time of program initiation, although some countries already had efforts for iodized salt or other iodine-supplementation intervention efforts under way prior to program legislation. Although the year of adoption of legislation of iodized salt was fairly recent for countries such as Myanmar (1998), China (1994), Thailand (1994), and Vietnam (1999), all of these countries have had relatively longstanding efforts devoted to the control of iodine-deficiency disorders. Thailand, for example, launched its first pilot project on salt iodization in 1965, and Myanmar launched its first pilot program for the control of iodine-deficiency disorders (by means of iodized salt) in 1969. In China, iodized salt was tested at selected sites from 1956 onward. In addition, in Sinjiang, China, over 700,000 injections of iodized oil were provided between 1978 and 1981, and an additional 300,000 to 400,000 injections were provided in 1982 [1] . In the case of Vietnam, the date of initiation of iodized salt implementation could not be identified. However, it is clear from the coverage rates reported (table 2, column G, and table 3, column F) that large efforts for iodized salt were already under way before legislation was adopted.
For the prevalence data, goiter detected by palpation was the indicator used in almost all cases. Only for Bangladesh, China, Laos, and Vietnam were repeat surveys of urinary iodine excretion also available.
Coverage data for iodized salt programs were available for nearly all countries and were used for the year of "during-intervention" outcome data whenever possible. In most cases, the coverage data reported reflect the percentage of households using adequately iodized salt (as established by individual country standards for the iodine content of salt, usually > 15 ppm); the coverage data in tables 3 and 4 were shown graphically in the second paper in this series [56] .
The rate of change in prevalence in percentage points per year was derived as follows:
follow up prevalence -baseline prevalence follow up year -baseline year Although the rate of change in prevalence (tables 3 and 4, column G) provides useful information about iodized salt programs at the country level, some caution should be taken before drawing conclusions about the impact of programs. First, as for other interventions, generally only data obtained before and during the intervention are available, without negative comparison groups.
Second, in most countries, only goiter rates are available (with the exception of Bangladesh, Laos, and Vietnam, in which urinary iodine is used also; China also has multiple rounds of urinary iodine excretion data available, but only data on median urinary iodine excretion values could be identified). Goiter has some drawbacks in terms of responsiveness to intervention and is a less preferred method of assessment of population iodine status [54, 57] . Moreover, assessment of goiter by palpation is regarded as a subjective means of assessing iodine deficiency. Low interobserver reliability is known to affect the results of goiter surveys, and the extent to which goiter is detected can be largely related to the level of training provided to the enumerators. An increase in goiter prevalence across time therefore may not reflect an actual trend in prevalence, but rather may be a consequence of improved training and more skilled detection of the manifestation of goiter.
The results of a recent national micronutrient survey in Nepal, in which palpation was compared with ultrasound of a subsample, highlight the questionable reliability of assessing goiter by palpation as a method of identifying iodine-deficient individuals [58] . The survey showed assessments of goiter by palpation and by ultrasound to be poorly correlated: for example, palpation showed a goiter prevalence of 57% and ultrasound a prevalence of 23% (although the cutoffs may not have been fully comparable).
Prevalence data from Bangladesh also illustrate the potential inconsistency in measurements of goiter by palpation. The increase in goiter prevalence rates reported for Bangladesh from 1981 (11.3%) to 1993 (47.1%) seems implausible. In this case, biochemical data are also available for trend assessment (see table 4 ), which seem to give more likely results, with an improving trend from 69% (urinary iodine < 10 µg/dl) in 1993 to 43% in 1999.
Evaluation findings
Impact of programs on clinical indicators of iodine deficiency
Given the established efficacy of salt iodization, a rapid improvement in the prevalence of iodine deficiency would be expected for those iodized salt programs successfully implemented at the country level. In a global review of progress in the control of micronutrient deficiencies [38] , we observed substantial declines in the prevalence of iodine deficiency in several countries that had achieved improved rates of household utilization of iodized salt over the same time period. Bolivia, Peru, and Cameroon, for example, all demonstrated a rapid improvement in goiter prevalence, with wider consumption of iodized salt reported. Across the three countries, the rates of change were calculated to range from a 2.0 to 5.5 percentage point improvement in goiter prevalence per year of program implementation; the average for seven countries with time-series data showing improvement was 2.3 percentage points per year. The rates of change, as shown in column G of table 3, are generally in this range for countries with widespread and sustained iodized salt coverage. The estimated rates of improvement in goiter prevalence vary from a decrease of 0.5 percentage point per year (Southern region of Laos) to a decrease of 6.5 percentage points per year (Myanmar) from national data. Vietnam, China, and Myanmar show the greatest impact. The rate of change for each of these countries is estimated as greater than a 2.5 percentage point decrease in goiter per year. Although both China and Vietnam showed rates of program coverage reaching around 90% (86.4% for Vietnam in 2000 and 91% for China in 1999), Myanmar reported a somewhat low rate of program coverage, with only 53% of households reported to have adequately iodized salt (> 15 ppm) in 1999. The rapid improvement in prevalence in Vietnam and China can therefore probably be explained by the wide program coverage achieved. Although the coverage rate reported for the iodized salt program in Myanmar seems somewhat low, the rapidly decreasing trend in prevalence for Myanmar could be attributed to complementary efforts that Myanmar has implemented for the control of iodine deficiency; these include control of iodine deficiency among schoolchildren by the use of iodinated drinking water.* Sri Lanka is the only country reporting a possible increase in the prevalence of goiter since the adoption of legislation for iodized salt, from 18.8% in 1989 to 21% in 2000. Legislation for iodized salt was adopted in 1993, and the program for iodized salt came into effect in 1995. The rate of change of goiter prevalence is calculated as a slight increase of 0.2 percentage point per year. This can be attributed to several possible factors. As discussed earlier, increased effort on the part of enumerators to identify goiter is a possible explanation for the finding. In addition, Sri Lanka has relatively low program coverage; less than 50% of households in Sri Lanka are reported to use iodized salt [35] . Further, among those households consuming iodized salt, Sri Lanka, more than many project countries, reports difficulties with the quality of iodized salt. Although the minimum iodine content for salt is established by legislation, lack of strict quality-control measures has caused the iodine content of the salt available to vary over a wide range. A survey in 2000 was reported to give the iodine content of salt available in markets as varying from 5.3 to 418 ppm.
Impact of programs on biochemical indicators of iodine deficiency
Trends in urinary iodine excretion can be estimated from survey results in Bangladesh, Laos, and Vietnam (table 4) . China has biochemical urinary iodine excretion data, but only median values were reported, preventing calculation of changes in prevalence. In addition to the urinary iodine data, each of these countries also has multiple rounds of national goiter data available. In Bangladesh, data on goiter are available for 1981 and 1993, and on urinary iodine for 1993 and 1999. Legislation for iodized salt was adopted in 1995, although production of iodized salt had been initiated earlier. As mentioned before, the changes in goiter rate are considered implausible. The urinary iodine excretion data suggest marked improvements in iodine deficiency since legislation for iodized salt was adopted. The 1993 survey showed 68.9% of the population to have urinary iodine levels below 10 µg/dl, falling to 43% in 1999. Over the same time period, coverage of iodized salt increased from 20% in 1994 to 70% in 1999. It seems highly plausible that the salt iodization led to the decrease in low urinary iodine excretion and the improvement in iodine status.
The data available for Laos and Vietnam further suggest that impact was achieved with a successfully implemented iodized salt program. In Laos, there were eight major salt manufacturers and many smallscale producers. The primary salt manufacturers have the capacity to produce 90% of the salt required for the country, making importation of noniodized salt less of a problem than in other project countries. The program is well coordinated among ministerial sectors and international organizations, includes information, education, and communication (IEC) activities as important program components, and implements routine monitoring to ensure the quality of iodized salt at the household level. Moreover, all data available for the program indicate high program coverage. Repeat data from two districts reported household utilization of iodized salt as 72% in 1996 and 96% in 1997-98. National program coverage for 2000 showed 94.3% of households to use iodized salt; 75.4% of these households had adequately iodized salt (> 15 ppm) when tested.
Data from Laos show a substantial decrease in the prevalence of iodine deficiency, as indicated by both goiter and urinary iodine data. In 1988, the baseline goiter prevalence was 25%; in 1993, it was 24.9% in the North and 14.9% in the South. The prevalence of urinary iodine less than 10 µg/dl in 1993 was 95%. The second round of national iodine-deficiency data was collected in 2000, five years after legislation for iodized salt had been adopted. The 2000 data showed goiter rates down to 9.1% in the North and 11.5% in the South; urinary iodine data indicated a marked improvement in the iodine status of the population, with 26.9% having urinary iodine less than 10 µg/dl. Iodized salt coverage for 2000 was reported as 75.4%.
In Vietnam, a high coverage of iodized salt was again related to an improving trend in iodine deficiency by both biochemical and clinical indicators. The most dramatic improvement appears to have occurred with the first efforts to iodize salt widely. Two periods were assessed: from 1993-5 to 1998, then 1998 to 2000. Goiter prevalence decreased from 27% to 15%, then 15% to 10% over this time. The prevalence of suboptimal urinary iodine excretion (< 10 µg/dl) decreased from 84% to 33%, then 33% to 31%. The rate of iodized salt coverage in 1998 was already high compared to that achieved by other countries: for 1998 it was reported as 72.8%, increasing to 86.4% in 2000.
Conclusions
From the country case studies and data available, it would seem that marked improvement in iodine deficiency occurs with programs that are well implemented. However, there are still examples of countries in which programs are not yet demonstrating a rapid improvement in signs of goiter, such as the Philippines, and no doubt some underserved areas in other countries are lagging. But overall, iodized salt is a resounding success story, bringing improved health and nutrition to millions of people
The rate at which goiter prevalence is reduced can be as high as 5 percentage points per year; the improvement seems fairly steady where repeated data are seen (e.g., Myanmar and Thailand), and the scarcer urinary iodine data support this. By the time iodized salt distribution reaches and remains at high coverage, goiter rates usually reach prevalences of 10% or less; but it may be that the last few percent reduction is indeed turning out harder to achieve.
Problems remain with coverage and quality control of iodized salt and the outreach to remoter and (usually) poorer areas.
Certain implications emerge for future monitoring and evaluation. Salt iodization is so easy to test, and so widely used, that it succeeds in giving a key indicator. Goiter prevalences are perhaps better than expected as a general measure in terms of responsiveness, and they have the important advantage of being widely available for baseline (or early in implementation) reference. They are, however, clearly very inaccurately assessed, and this needs to be improved either with better technology (e.g., ultrasound) or more standardized training. Measurement of urinary iodine is not as widely available and also has the drawback that it assesses current intake; in this respect, the value that it adds to salt iodine testing may not be so great.
None of these tests measure the functional consequences of the deficiency; goiter itself can be innocuous. This argues for wider application of testing for thyrotropin in newborns (usually performed on cord blood, for which rapid immunoassay methods are now available). Perhaps more stress should be on this approach, complementing salt iodine testing.
Finally, in countries with low program coverage, there are likely to be large pockets of individuals particularly vulnerable to iodine-deficiency disorders. Because of the serious risk of damage in utero, in some instances complementary measures for the control of iodine-deficiency disorders may need to be considered until higher program coverage of iodized salt can be achieved. Targeting women of childbearing age or pregnant women with oral iodine supplementation, either as a single large dose of iodized oil, or in multiple micronutrient supplements provided as part of antenatal care, may be warranted in places where iodized salt may not yet be readily available or utilized.
Iron
What is known from efficacy trials
The results from a number of recent iron-supplementation trials were compiled by Beaton and McCabe [59] , in which data from eight controlled trials providing iron supplementation to pregnant women were reanalyzed to study the efficacy of weekly vs. daily supplementation. For all of the trials, there were two treatment groups: one receiving weekly and one receiving daily iron tablet supplementation (except for the trial in China, which had a third study group that received a higher dose of iron). The results of the studies (table 5) are interesting here for consideration of the possible sizes of effects with supervised iron supplementation.
In all eight studies, daily iron supplementation to pregnant women resulted in an improvement in anemia prevalence from baseline to post-intervention. The extent of the impact demonstrated varied widely across studies. The decrease in anemia prevalence from baseline to follow-up ranged from 10.8 percentage points (Malawi) to 60 percentage points (Korea). The criterion of anemia in all studies on pregnant women was defined as hemoglobin 110 g/L, with exception of the study in Mexico, which used 120 g/L as the criterion. The 60 percentage point improvement in anemia observed in Korea was exceptional; no other study included in the review showed an improvement in anemia prevalence by more than 30 percentage points. In general, the more controlled studies showed a higher rate of improvement in anemia from baseline to postintervention. The trials conducted in Maluku, China, and Mexico, for example, were all tightly controlled; high compliance for the regimented dosing schedule among the participants would therefore be expected. In the case of the Malawi study, very few controls were implemented in the study design, and likewise, the difference in anemia prevalence from baseline to follow-up was the lowest (10.8 percentage points) for all the intervention trials reviewed. A consistent pattern of improvement in anemia was clearly observed in all studies for those groups provided with iron supplementation. Among the groups treated with daily supplementation, the median and mean decreases in anemia prevalence were 17 and 19.7 percentage points (excluding Korea, with a mean 60 percentage point decrease, regarded as an outlier).
From these and many earlier studies (reviewed extensively by Viteri [60] ), substantial improvement in anemia prevalence is expected from daily (or weekly) ingestion of iron supplements by pregnant women, and probably greater improvement from ingestion of iron supplements by nonpregnant women. In theory, similar decreases could be achieved from a wide-scale program, although it is likely that under less controlled conditions a slower rate of improvement would be seen, even for those programs generally successfully implemented. In fact, much less is known about the extent to which large-scale iron-supplementation programs demonstrate effectiveness. Among countries, lack of data and limited capacity for program monitoring often preclude drawing firm conclusions about the effectiveness of iron-supplementation programs. In many cases, prevalence data cannot be linked to programs implemented, and it is often difficult to assess program participation. In countries located in subtropical areas, there are complications in assessing the prevalence of anemia caused by iron deficiency. Recent analysis of anemia data concluded that there was little evidence for overall change in the populations of developing countries, although direct trend estimates from surveys are very scarce [38, 61] .
Iron-supplementation programs have the added problem of monitoring tablet compliance among program participants. Because these programs are designed to provide regular supplementation (usually daily) to women throughout pregnancy, the extent of the impact achieved would be expected to be related, in part, to the number of tablets a woman takes during pregnancy. There is, however, no easy or routine way to monitor daily consumption of iron tablets by pregnant women participating in a program of national scale. Of the project countries, Vietnam and Thailand have the most comprehensive data on iron-supplementation programs. Although several other project countries have at least two rounds of anemia data available, the prevalence data cannot usually be linked to the programs implemented. Lack of process data and of knowledge of the underlying trends limits the possibility for evaluation analysis across countries. Even in the case of Thailand and Vietnam, complete data are not available. Given, however, that both countries have some process data available, various sources of data on anemia prevalence, and some information on program coverage, an assessment of program effectiveness for these countries has therefore been undertaken. The preliminary findings for each of these countries are discussed below.
Evaluation findings
Assessment of program effectiveness in Thailand
In Thailand, the main strategy implemented for the control of anemia among pregnant women is daily supplementation with iron/folate tablets [36] . The policy for supplementation recommends that pregnant women be provided with iron tablets from their first appearance at the antenatal clinic through four to six weeks postpartum. The main mechanism for program delivery is through the health-care system, with community health workers (village health communicators and village health volunteers) playing an important role in encouraging pregnant women to visit health centers for antenatal care and prophylactic iron supplementation. Although limited attention has so far been given to assessing the effectiveness of the iron-supplementation program, data on anemia and access to health services are available from various sources and can provide useful information about program effectiveness. Data on the prevalence of anemia are available from nationally representative surveys (1986 and 1996-97) and from surveillance data collected at health centers. However, the data available do have limitations for assessing program effectiveness. It is possible, for example, that the sampling design of the surveys may have been influenced by an over-or underestimation of the prevalence reported for anemia. For the national survey, the hemoglobin of pregnant women was measured in sampled households, which were defined by the presence of children under five years of age; in the case of surveillance data, hemoglobin was measured in areas with more sophisticated health services available, therefore probably resulting in an underestimation of the prevalence of anemia. In addition, none of the available anemia prevalence data could be disaggregated by gestational age. It is therefore unclear how accurately the prevalences reported reflect the extent of the problem.
Data on coverage of antenatal care are also available, but limited. Due to inadequate capacity for monitoring of program coverage, a proxy indicator of antenatal-care coverage is used, defined as the number of antenatal-care visits made during pregnancy, with four or more visits throughout pregnancy recommended as optimal. Using antenatal visits as a proxy for program coverage assumes, however, universal supplementation to all women receiving antenatal care during pregnancy and, therefore, could to some extent result in an overestimation of coverage achieved. An improving trend in prevalence among pregnant women is evident from the available data (table 6) . The two most recent national surveys (1986 and 1996-97), for example, show a decline in the prevalence of anemia among pregnant women.
Over the period of 10 years, a substantial and important decline in anemia prevalence was estimated for each region. Anemia prevalence among pregnant women in the Central/East, North, Northeast, and Southern regions of the country declined from 32% to 12 %, 42% to 8 %, 39% to 27 %, and 48% to 13 %, respectively. Other data support the conclusion of a decrease in prevalence indicated by the national data. Surveillance data show a decline of about 10 percentage points, from 27 percent to 17 percent, between 1988 and 1999. In addition, small research studies have shown that the severity of anemia among pregnant women has also declined. Moreover, an improving trend in attendance at antenatal clinics is also evident over time, with a high rate of antenatal coverage achieved in recent years. It is reasonable to suggest, although this is not proven, that part of the improvement may indeed be due to the iron-supplementation program.
The trend in anemia prevalence can be determined from data available on other demographic groups. Data on anemia prevalence among men and young children should indicate the underlying trend in anemia status, since no programs for these groups are yet implemented in Thailand. For men, two rounds of Health Examination Surveys (1991 and 1996-97) are available. For each region, the prevalence of anemia decreased across time; for two of the five regions, the decrease was substantial, amounting, for example to 20 percentage points in the Central-East region. The decreases for these groups (not targeted for iron supplementation) are in the same range as those for pregnant women. This casts some doubt on the effect achieved by the iron-supplementation program alone.
Assessment of program effectiveness in Vietnam
As in Thailand, the main strategy for the control of iron-deficiency anemia in Vietnam is providing daily iron tablet supplementation to pregnant women [37] . The program for iron supplementation was implemented in 15% to 20% of the country in 1995 to 2000. Programs for weekly supplementation to groups such as children and adolescents 6 to 15 years old, nonpregnant women 15 to 35 years old, and infants and children are also implemented in selected areas, but these interventions are still in the pilot testing phase. The protocol for the iron-supplementation program recommends daily iron tablets to be taken by pregnant women from first presentation at the antenatal clinic to one month after delivery. Although the capacity for program monitoring and supervision is reported to be limited, some data are available for crude assessment of the extent of the impact that may have been so far achieved.
Nationally representative data on anemia prevalence are available from a 1995 national anemia and nutrition risk survey and a national survey launched in 2000. As seen in Thailand, a strong improving trend in anemia prevalence is observed among pregnant women. In Vietnam, anemia prevalence rates of 52.7% and 32.2% were reported for pregnant women for the years 1995 and 2000, respectively, a 20.5 percentage point decrease in five years. Although other demographic groups also show a decrease in anemia prevalence across years, in this case for no other groups is the decrease as substantial. For nonpregnant women, children 0 to 60 months of age, and men, the respective decreases in anemia prevalence from 1995 to 2000 were reported to be 15.9, 11.2, and 6.3 percentage points. From this perspective, the more substantial decrease in anemia among those groups for which supplementation programs are implemented might indicate some program impact. Unfortunately, the program coverage data do not support this conclusion. From 1995 to 2000, a substantial decrease in program coverage was observed. Whereas 425,000 women were targeted for iron supplementation in 1995, less than 10% of that number (40,000) was targeted in 1996. Likewise, the number of provinces, districts, and communes to benefit from the program showed a pattern of similar decline between the years 1995, 1996, and 2000.
The conclusion for Vietnam (as for Thailand) has therefore to be that the decrease in anemia was probably real, but without better evaluation it is not possible to ascribe this to the supplementation program. Certainly part was due to a nonprogrammatic underlying trend.
Results from other countries
The limitations of the data available for evaluation of the iron-supplementation program in Thailand and Vietnam are common to most countries with national programs. In fact, other countries with programs for iron supplementation to pregnant women often have substantially fewer data available for assessment of program effectiveness. Of the project countries, Bangladesh, Myanmar, Indonesia, and the Philippines have data on anemia among pregnant women available for recent years (table 6), but few other data on the program.
Bangladesh shows a substantial decrease in anemia prevalence; an improvement of more than 27 percentage points among pregnant women, from 77% to 49%, was reported from 1981 to 1997. In Myanmar, Indonesia, and the Philippines, on the other hand, the rate of anemia among pregnant women appeared stagnant across time, despite implementation of national ironsupplementation programs. In Myanmar the rate of anemia remained at about 58% from 1993 to 1995; in Indonesia it remained at roughly 50% from 1991 to 2001; and in the Philippines it increased from 43.6% in 1993 to 50.7% in 1998. The lack of improvement probably stems from difficulties common to program implementation, as well as lack of change in the underlying prevalence of anemia.
Conclusions
The rate of improvement demonstrated by the efficacy studies compiled for the Beaton and McCabe [59] review thus appear larger than those seen at the program level, even when some improving trends are seen (as in Bangladesh, Thailand, and Vietnam). Improvements of the magnitude of 20 percentage points are rarely observed, and in those cases when such change across time is indicated, the effect can rarely be confidently attributed to program intervention. The lack of firm conclusions that can be drawn about program effectiveness highlights the importance of increased efforts to improve capacity for program monitoring and evaluation. Comparable surveys on anemia prevalence among supplemented groups in program and nonprogram areas, and data on program coverage across time and use of antenatal services, are essential for strong conclusions to be made about the effectiveness of programs. Information about the time of gestation on the date of blood collection and about tablet compliance would further help to elucidate the extent to which iron-supplementation programs are benefiting targeted populations, although such data are more difficult to obtain.
Summary of lessons learned on micronutrient-deficiency control program effectiveness and associated recommendations Program evaluation
Micronutrient-deficiency control programs have been greatly extended at the national level in the last 10 to 15 years. However, rigorous evaluation of these is scarce, so that conclusions on impact are tentative and based mainly on indirect evidence.
The effects of programs need to be distinguished from underlying trends of improvement in population nutritional status. This underlying improvement is probably occurring for clinical vitamin A deficiency, but probably not for iodine and iron deficiencies (i.e., in the absence of intervention). Nonetheless (see below), taking account of this, it is plausible that twiceyearly distribution of vitamin A capsules, which has attained high coverage in most of the countries studied, has contributed to the near-elimination of clinical vitamin A deficiency in children, and that the use of iodized salt has brought goiter rates steadily down in the general population. For anemia, however, where significant improvement over time is seen (which is uncommon but may be occurring in Bangladesh, Thailand, and Vietnam), the existing information is insufficient to allow the trend to be ascribed to intervention, and there is evidence of improving trends in Thailand and Vietnam that are not due to iron programs. For all deficiencies systematic prospective evaluation is urgently needed.
Intervention efficacy
Efficacy trials have demonstrated that high-dose vitamin A supplementation of children results in significant reductions in the prevalence of clinical vitamin A deficiency.
Studies in India, Indonesia, the Philippines, and elsewhere have demonstrated that vitamin A supplementation is efficacious for the prevention and treatment of xerophthalmia: twice-yearly supplementation has resulted in a reduction of clinical vitamin A deficiency to nearly zero (down by 1 to 5 percentage points). The results for subclinical vitamin A deficiency are uncommon; and those available give equivocal results.
Many trials have demonstrated the efficacy of iodine supplementation in reducing the prevalence of goiter and other signs of iodine-deficiency disorders and improving population iodine status.
Mechanisms of supplementation tested include lipiodol injections, oral iodized oil supplementation, and iodization of salt. The results of the studies indicate efficacy for the prevention of cretinism, improvement of psychomotor skills and cognitive development, and prevention and treatment of goiter. Study countries in Asia include China, India, Indonesia, and Papua New Guinea.
Trials have demonstrated the efficacy of iron tablet supplementation in reducing anemia prevalence.
The mean reduction of anemia prevalence was roughly 20 percentage points with daily supplementation. The study countries included Indonesia, Malawi, China, and Korea. The magnitude of improvement appears to be associated with the extent of supervision of adherence to dosing regimes in the studies, indicating that efficacy is linked to the degree of participant compliance with the dosing regime.
Coverage of national programs
The coverage of vitamin A capsule distribution programs has exceeded 70% in most study countries (Bangladesh, Myanmar, Philippines, Vietnam, and Laos).
Only India (40%), Indonesia (66%), and Cambodia (63%) were estimated to have lower rates of coverage of vitamin A capsules. The utilization of national immunization days as the foundation for campaign-style programs accounts to a significant degree for the high coverage rates achieved. Coverage estimates derive in large part from program-monitoring data.
In countries implementing national iodized salt programs, the coverage reaches 60% to 90% of households with adequately iodized salt.
Quality control, maintaining coverage, and further measures to reach underserved populations should become the current priorities. Coverage estimates are normally based on testing for the level of salt iodization in households in sample surveys.
Of the three micronutrients, coverage of iron tablet supplementation is the least well documented due to inadequate program-monitoring systems, lack of population survey data, and lack of accurate estimates of adherence to the dosing regimen.
Only two countries have reasonable monitoring systems. Vietnam indicates a coverage level of 15% to 20% of the country, and coverage is reported to be quite high in Thailand based upon estimates of antenatalcare attendance.
National program effectiveness
Vitamin A capsule supplementation of children 6 to 59 months of age has plausibly contributed to the reduction in clinical vitamin A deficiency and its near-elimination in many countries (fig. 3) .
The national rate of decline in measured nightblindness in project countries in Asia ranges from -0.15 percentage point per 10 years (Vietnam) to -1.76 percentage points per 10 years (Bangladesh). Although the level of impact appears to be less than in controlled trials, it is in the range of 0.5 percentage point per 10 years. This rate depends on contextual and program factors such as high baseline prevalence and high program coverage. Both of these factors may account for the exceptionally high impact seen in Cambodia (-7.7 percentage points per 10 years) and Bangladesh (-1.76 percentage points per 10 years). Most countries have multiple programs implemented (see the previous article in this issue on Implementation), so the synergistic effects of multiple intervention strategies (combined with the usage of national immunization days as the mechanism for delivery of vitamin A capsule) may account in part for the impact seen.
The impact of vitamin A capsule supplementation on children's biochemical vitamin A status (serum retinol)
in national programs may be lower than the impact on clinical vitamin A deficiency.
Limited research from national programs in the Philippines indicates that the impact of supplementation on serum retinol levels is of shorter duration than the impact on clinical signs of deficiency. This would in part explain the slight increase in subclinical vitamin A deficiency in the Philippines during implementation of vitamin A capsule programs. The collection of biochemical and clinical data in the same subjects would contribute to the clarification of the nature and extent of impact to be expected from supplementation. Additionally, more research is needed to evaluate the relative benefits of alternative dosing regimens (e.g., two times vs. three times a year). Similar results and conclusions were reached in a recent study in India [42] .
National data on salt iodization show a consistent reduction in the prevalence of iodine-deficiency disorder symptoms (e.g., prevention and treatment of goiter); the rates of cretinism and other results of iodine deficiency are almost certainly falling too ( fig. 4) .
At the population level, the most common mechanism for providing iodine is salt iodization. This has largely superseded the use of iodized oil, given orally or by injection. The data for study countries indicate a steadily improving trend in the prevalence of clinical iodine-deficiency disorders, consistent with a dramatic global trend of decreased prevalence of iodine-deficiency disorders with the implementation of national salt iodization programs (reductions in goiter prevalence of 20 to 54.5 percentage points per 10 years). There is enormous variation in the improvement in the prevalence of iodine-deficiency disorders among study countries, from 0.5 percentage point per year (Southern region of Laos) to 6.5 percentage points per year (Myanmar). Vietnam, China, and Myanmar showed improvement of greater than 2.5 percentage points per year. Variation in prevalence estimates is likely to result in part from measurement error: increased awareness of the value of monitoring of goiter is thought to result in higher estimates, leading to spurious conclusions of increased goiter prevalence.
The evaluation of the impact of salt iodization programs on biochemical iodine status is limited by a lack of data (and a lack of urinary iodine data linked to program data).
The iodine-deficiency disorders, in contrast to a worsening, and quite possibly spurious, trend shown by the goiter data.
Although trials have demonstrated the efficacy of iron supplementation in reducing the prevalence of anemia, the interpretation of national-level data is not so clear.
The rate of improvement would be expected to be less in national programs than in controlled trials because of reduced adherence to daily (or weekly) dosing protocols in the community setting. In terms of evaluating national program effectiveness in reducing anemia, only Thailand and Vietnam have anemia prevalence and program coverage data available. In Thailand, daily supplementation of pregnant and postpartum women appears to have been associated with a substantial decline in anemia prevalence (of 1 to 3.5 percentage points per year in different regions of the country). However, data from men and from children under five years of age suggest a comparable trend in anemia improvement. This calls into question the degree to which improvement among pregnant and lactating women can be attributed to program impact. In Vietnam, the data suggest that populations (pregnant women, nonpregnant women, and children under five) showed lower prevalence rates of anemia. However, the data available do not allow the conclusion to be drawn that the differences result from program impact. Anemia data across other study countries suggest that anemia-unlike clinical vitamin A deficiency and clinical iodine-deficiency disorders-is not showing marked improvements, but remains high. This may be due to common constraints to program initiation (see Part I in this issue) and implementation (see Part II in this issue), or to changes in other determinants of anemia. Perhaps even more than vitamin A deficiency and iodine-deficiency disorders, priority is needed on monitoring and evaluation of national iron-deficiency control, to better understand how anemia may be reduced in vulnerable population groups.
Next steps in evaluation
Given the substantial financial and technical commitment required to implement national micronutrient-deficiency control programs, it is vital that investment enable the evaluation of the impact of these programs.
Although further development of systems for monitoring program coverage is necessary in the study countries, even coverage data are inadequate to monitor program impact. Collection of process and outcome data, particularly through representative sample surveys and program-monitoring systems, is required for the assessment of a program's effects. Research on noninvasive methods of assessment (for anemia and subclinical vitamin A deficiency) for use in routine surveys would be helpful for this.
The prevalence of clinical manifestations of micronutrient deficiencies-including vitamin A deficiency (xerophthalmia) and iodine-deficiency disorders (goiter)-is in sharp decline in many countries. As a result, it is becoming increasingly important to collect data on subclinical deficiency (e.g., biochemical data) to assess program impact.
The collection of multiple rounds of national serum retinol or urinary iodine data is infrequent. These indicators will increase in importance for evaluation as the nutritional status of populations improves and the effects of deficiency are largely subclinical. More research is required to clarify the utility and interpretation of biochemical indicators for impact assessment.
Global trends in micronutrient deficiency data indicate possible secular trends of improvement.
The widespread reduction in the prevalence of clinical vitamin A deficiency, as well as the reduction of anemia in program and nonprogram groups in Thailand (and probably Bangladesh and Vietnam), highlights the importance of differentiating secular (non-program-related) trends from program impact. Because such trends may coincide with program implementation, the design of evaluation studies needs to make comparisons of groups before and after intervention, and with and without intervention, to estimate the effect attributable to program participation.
In conclusion, the clearest evidence of program effectiveness is found with salt iodization.
The national-level implementation of salt iodization programs, with adequate provision for salt accessibility and consumption, is associated in study countries with an often sharp reduction in the prevalence of iodinedeficiency disorders. The effectiveness of vitamin A supplementation in the reduction of clinical vitamin A deficiency is likely, but its effectiveness on biochemical indicators of vitamin A is unclear. Additionally, the anticipated phaseout of national immunization days following the virtual eradication of polio calls for more targeted research on alternative and effective intervention models. Finally, evidence on the effectiveness of iron-deficiency programs, specifically iron tablet distribution, is inconclusive because of lack of accurate coverage data and evidence that improvements in iron status may be due to improved living conditions where data are available (Vietnam and Thailand).
